UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1388-4
Program Prior Authorization/Notification
Medication Vijoice® (alpelisib)
P&T Approval Date 6/2022, 6/2023, 6/2024, 6/2025
Effective Date 9/1/2025
1. Background:
Vijoice® (alpelisib) is a kinase inhibitor indicated for the treatment of adult and pediatric patients
2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum
(PROS) who require systemic therapy. This indication is approved under accelerated approval
based on response rate and duration of response. Continued approval for this indication may be
contingent upon verification and description of clinical benefit in a confirmatory trial(s).
2. Coverage Criteria a:
A. Initial Authorization
1. Vijoice will be approved based on all of the following criteria:
a. Diagnosis of PIK3CA-Related Overgrowth Spectrum (PROS)
-AND-
b. Patient is 2 years of age or older
-AND-
c. Patient has severe manifestations of PROS requiring systemic therapy
Authorization will be issued for 12 months.
B. Reauthorization
1. Vijoice will be approved based upon the following criterion:
a. Documentation of positive clinical response to Vijoice therapy.
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2025 UnitedHealthcare Services Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits, Medical Necessity, and/or Step Therapy may be in place.
4. References:
1. Vijoice [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2024.
Program Prior Authorization/Notification – Vijoice® (alpelisib)
Change Control
6/2022 New program.
6/2023 Annual review. Added state mandate footnote. Updated references.
6/2024 Annual review. Updated initial authorization to 12 months. Updated
references.
6/2025 Annual review without changes to coverage criteria.
© 2025 UnitedHealthcare Services Inc.
2